EHTH vs BEAM

For growth investors, Beam Therapeutics Inc.

(BEAM) is the stronger pick with 120. 0% revenue growth year-over-year, versus 4. 1% for eHealth, Inc. (EHTH). Analysts rate Beam Therapeutics Inc. (BEAM) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Beam Therapeutics Inc.

(BEAM) delivered a total return of -55. 6%, compared to -97. 3% for eHealth, Inc. (EHTH). Over 10 years, the gap is even starker: BEAM returned +67. 8% versus EHTH's -85. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), eHealth, Inc.

(EHTH) is the lower-risk stock at 1. 99β versus Beam Therapeutics Inc. 's 2. 14β — meaning BEAM is approximately 8% more volatile than EHTH relative to the S&P 500. On balance sheet safety, eHealth, Inc. (EHTH) carries a lower debt/equity ratio of 14% versus 24% for Beam Therapeutics Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Beam Therapeutics Inc.

(BEAM) is pulling ahead at 120. 0% versus 4. 1% for eHealth, Inc. (EHTH). On earnings-per-share growth, the picture is similar: Beam Therapeutics Inc. grew EPS 82. 3% year-over-year, compared to 71. 4% for eHealth, Inc.. Over a 3-year CAGR, BEAM leads at 31. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

eHealth, Inc.

(EHTH) is the more profitable company, earning 7. 2% net margin versus -57. 2% for Beam Therapeutics Inc. — meaning it keeps 7. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EHTH leads at 12. 4% versus -274. 6% for BEAM. At the gross margin level — before operating expenses — EHTH leads at 97. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, EHTH (10.

4% yield) pays a dividend. BEAM does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, eHealth, Inc.

(EHTH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (10. 4% yield). Beam Therapeutics Inc. (BEAM) carries a higher beta of 2. 14 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EHTH: -85. 2%, BEAM: +67. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (EHTH (Financial Services) and BEAM (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: EHTH is a small-cap income-oriented stock; BEAM is a small-cap high-growth stock. EHTH pays a dividend while BEAM does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.